Nathan Pennell, SVP and Head of Global Medical Oncology at Bristol Myers Squibb, shared a post on LinkedIn:
“Thank you to Professor Chamato, Associate Professor Segiura, and the entire CCII team for hosting Bristol Myers Squibb at the center where immune checkpoint inhibitors were discovered! I came away incredibly impressed with their work on biomarkers to predict benefit and toxicity from IO and cell therapy. I look forward to continuing our strong collaboration to bring life saving translational science to patients.
Other articles featuring Nathan Pennell.